What is AIDX's current stock price?

AIDX (20/20 Biolabs, Inc. Common Stock) is currently trading at $0.98 with a market cap of $5.5M.

What sector is 20/20 Biolabs, Inc. Common Stock in?

20/20 Biolabs, Inc. Common Stock (AIDX) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is AIDX a good stock to buy?

Analysts have a Buy consensus on AIDX with a price target of $5.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AIDX 20/20 Biolabs, Inc. Common Stock

Healthcare

$0.98-18.67%ClosedMarket Cap: $5.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.94

P/S

4.23

EV/EBITDA

-0.56

DCF Value

$-15,335.12

FCF Yield

-33.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

28.4%

Operating Margin

-266.7%

Net Margin

-320.9%

ROE

111.7%

ROA

-72.3%

ROIC

-102.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$353.4K	$-2.1M	$—
FY null	$2.05B	$-3.74B	$—
Q3 null	$418.0K	$-825.5K	$—
Q4 null	$536.1K	$-1.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Zhou Jimingofficer: Chief Operating Officer

SellMon Apr 06

Bergman Alan B.officer: Chief Financial Officer

SellMon Apr 06

Cohen Jonathan Mdirector, 10 percent owner, officer: Chief Executive Officer

SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

-0.42

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.